Mandate

Vinge represents the Swiss heating, cooling and washing technology company Schulthess Group

April 11, 2011

Vinge represents the Swiss heating, cooling and washing technology company Schulthess Group AG (”Schulthess”) and its owners in connection with NIBE Industrier AB’s (publ) (“NIBE”) acquisition of 31.13% of the shares in Schulthess. NIBE also announces a recommended voluntary public tender offer to the remaining shareholders. The offer, which is a mixed cash and share offer, corresponds to a total equity of CHF 638 million, approximately SEK 4.4 billion. Assuming full acceptance of the offer, shareholders in Schulthess will, upon completion, hold approximately 14.8% of the share capital and 7.1% of the votes in NIBE. The offer is conditional upon certain conditions and closing is expected in the beginning of July.

Schulthess is listed on Six Swiss Exchange. NIBE is listed on NASDAQ OMX Stockholm and will, in connection with the offer, apply for secondary listing of its B-shares on SIX Swiss Exchange.

Partner Rikard Stenberg together with Johan Thiman and Carolina Walther represent Schulthess and its owners.

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025